How it works
Methodology
From a goal, to a status, to a source, to a price. Each step and the rule behind it.
1.Goals come first
The site is organized by what a reader wants to change. There are 5 goals: weight, sexual health, longevity, recovery and sleep.
A peptide appears under a goal because readers look it up for that goal. That placement is a filing decision. It is not a claim that the peptide works for it.
2.The regulatory gate
Every peptide has one status. The status decides what the site may show.
- FDA-approved or Legal to compound: research, seller links and prices.
- Approved as a brand only: the branded product only. A compounded version gets no seller link and no price.
- Research only: research only. No seller, no price.
- Status not yet reviewed: treated as research-only until its source is read.
Where FDA limits a status to certain forms, the gate applies per form. A topical form can pass while an injection of the same peptide does not.
Each status is read from an FDA document and dated. It is re-read when FDA publishes a change. One function applies the gate, and the goal pages, prices and seller lists all call it.
3.The register, as read
| Peptide | Status | Rests on | Read |
|---|---|---|---|
| Semaglutide | FDA-approved | Wegovy (semaglutide) injection, NDA 215256, approved for chronic weight management. Source | September 2026 |
| Tirzepatide | FDA-approved | Zepbound (tirzepatide) injection, NDA 217806, approved for chronic weight management. Source | September 2026 |
| Liraglutide | FDA-approved | Saxenda (liraglutide) injection, NDA 206321, approved December 23, 2014 for chronic weight management. Source | September 2026 |
| Orforglipron | FDA-approved | Foundayo (orforglipron) tablets, NDA 220934, approved April 1, 2026 for chronic weight management. Source | September 2026 |
| Sermorelin | Legal to compound | Component of an FDA-approved drug (GEREF, sermorelin acetate). FDA determined in 2013 that GEREF was not withdrawn from sale for reasons of safety or effectiveness. Source | September 2026 |
| NAD+ | Legal to compound | Nicotinamide Adenine Dinucleotide (NAD) is in 503A Category 1 (bulk drug substances under evaluation), covered by FDA's interim compounding policy (list updated May 14, 2026). Source | September 2026 |
| Glutathione | Legal to compound | Glutathione is in 503A Category 1 (bulk drug substances under evaluation), covered by FDA's interim compounding policy (list updated May 14, 2026). Source | September 2026 |
| GHK-Cu | Legal to compound | "GHK-Cu (except for injectable routes of administration)" is in 503A Category 1 (list updated May 14, 2026). The injectable route is on no list. Source | September 2026 |
| PT-141 (bremelanotide) | FDA-approved | Vyleesi (bremelanotide) injection, NDA 210557, approved June 21, 2019 for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Source | September 2026 |
| Tesamorelin | Approved as a brand only | Approved only as Egrifta, for excess abdominal fat in adults with HIV-associated lipodystrophy. Its label says it is not indicated for weight loss. Egrifta became a biologic (BLA) on March 23, 2020, and FDA says compounded versions of these products do not qualify for the 503A or 503B compounding exemptions. Source | September 2026 |
| MOTS-c | Research only | On no 503A list (not in Categories 1–3 of the May 14, 2026 update). The FDA's compounding advisory committee voted 7–5 (two abstentions) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking. Source | September 2026 |
| BPC-157 | Research only | On no 503A list (removed from Category 2 in April 2026, never in Category 1). The FDA's compounding advisory committee voted 8–6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking. Source | September 2026 |
| Kisspeptin | Research only | Kisspeptin-10 is in 503A Category 2 (bulk drug substances that raise significant safety risks), placed there September 29, 2023 and still listed in the May 14, 2026 update. FDA cites a possible risk of immunogenicity and peptide-related impurities, and says it has no, or only limited, safety information for the proposed routes. Source | September 2026 |
| CJC-1295 | Research only | On no FDA compounding list. The name does not appear in the 503A bulk drug substances categories (updated May 14, 2026) or in the 503B categories (updated March 21, 2025), so neither a 503A pharmacy nor a 503B outsourcing facility has a listed route to it. Source | September 2026 |
| Ipamorelin | Research only | "Ipamorelin Acetate" is in 503B Category 2, bulk drug substances that raise significant safety risks (list updated March 21, 2025). It is named on no 503A list, so neither an outsourcing facility nor a 503A pharmacy has a listed route to it. Source | September 2026 |
| Epitalon | Research only | On no FDA compounding list. Neither "Epitalon" nor "Epithalon" appears in the 503A bulk drug substances categories (updated May 14, 2026) or in the 503B categories (updated March 21, 2025). Source | September 2026 |
| DSIP | Research only | On no FDA compounding list. The name does not appear in the 503A bulk drug substances categories (updated May 14, 2026) or in the 503B categories (updated March 21, 2025). Source | September 2026 |
| TB-500 | Research only | On no FDA compounding list: absent from the 503A categories (updated May 14, 2026) and the 503B categories (updated March 21, 2025). FDA's compounding advisory committee voted 8-6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking. Source | September 2026 |
| Retatrutide | Research only | FDA states that retatrutide and cagrilintide "cannot be used in compounding under federal law", and that they "are not components of FDA-approved drugs and have not been found safe and effective for any condition". It is named on no 503A or 503B list. Source | September 2026 |
| MK-677 | Research only | "Ibutamoren Mesylate" is in 503A Category 2, bulk drug substances that raise significant safety risks (list updated May 14, 2026), and in 503B Category 2 (updated March 21, 2025). Both lists bar it for the same stated reason. Source | September 2026 |
| Thymosin alpha-1 | Research only | "Thymosin alpha-1" is in 503B Category 3, bulk drug substances nominated without adequate support (list updated March 21, 2025). It is named on no 503A list, so no listed compounding route exists for it. Source | September 2026 |
| Oxytocin | Status not yet reviewed | Not yet read. Treated as research-only. | Not read |
| KPV | Research only | On no FDA compounding list. KPV appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025). FDA's compounding advisory committee voted 8-6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking. Source | September 2026 |
| Melanotan II | Research only | On no FDA compounding list. Neither "melanotan" in any spelling nor the related approved substance afamelanotide appears in the 503A bulk drug substances categories (updated May 14, 2026) or the 503B categories (updated March 21, 2025). Source | September 2026 |
| AOD-9604 | Research only | On no FDA compounding list. AOD-9604 appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025). Source | September 2026 |
| Semax | Research only | On no FDA compounding list. Semax appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025). Source | September 2026 |
| Selank | Research only | On no FDA compounding list. Selank appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025). Source | September 2026 |
| SS-31 | Research only | On no FDA compounding list. Neither SS-31 nor elamipretide, the name it is studied under, appears in the 503A bulk drug substances categories (updated May 14, 2026) or the 503B categories (updated March 21, 2025). Source | September 2026 |
| LL-37 | Research only | On no FDA compounding list. Neither LL-37 nor cathelicidin, the family it belongs to, appears in the 503A bulk drug substances categories (updated May 14, 2026) or the 503B categories (updated March 21, 2025). Source | September 2026 |
| 5-Amino-1MQ | Research only | On no FDA compounding list. 5-Amino-1MQ (5-amino-1-methylquinolinium) appears in neither the 503A bulk drug substances categories (updated May 14, 2026) nor the 503B categories (updated March 21, 2025). Source | September 2026 |
4.How evidence is sourced
Findings come from the study itself. A paper is identified by its PubMed ID where it has one, and linked to its record.
Every finding names what was studied: people, animals or cells. For people, the page gives the number studied, the dose and the duration where the paper reports them.
Animal and cell results are reported as animal and cell results. Where no human study exists, the page says so.
5.How prices are read
A price is the figure the seller publishes on its own site. It carries the date it was read. No price here was confirmed by completing a checkout.
Some sellers publish a membership or program fee you cannot avoid, separate from the drug price. That fee is added before any comparison. The total is our arithmetic on the seller’s own figures.
A price billed every four weeks is charged 13 times a year, so we rank it at its calendar-month figure: the price times 13, divided by 12. Where that figure appears it reads as our calendar-month conversion, next to the seller’s own four-week price. A price per vial or per kit states no duration, so it keeps its own unit and is never ranked against a month.
A monthly price under $50 for a peptide whose dose steps up is treated as an introductory offer. It is marked promotional and is not used to rank.
6.Order on a seller list
On a ranked board, partners are listed first and labeled Partner. That part of the order is commercial, and it is disclosed on the board itself. Every other seller list on this site (a guide’s sellers, a goal’s sellers) is ordered by fit or alphabetically, never by partnership, and says which.
After the partner group, sellers are ordered by our clinical-fit rubric: the care around a prescription, with price as a minor input. It reads these facts about each seller. A fact the seller’s pages do not answer is left out of that seller’s order and the other weights are scaled up to fill it; it is never counted as a zero. Labs count only for a peptide whose effect is read in the blood, and the dose-price mark only for a peptide whose dose steps up.
- 25%Prescriber and intake. Whether the seller names the clinicians who prescribe, and whether you speak to one before a prescription is written or only fill in a form.
- 15%Labs where the compound calls for them. Bloodwork included, offered or never mentioned. Scored only for a compound whose effect is read in the blood; for the others it is left out.
- 15%Pharmacy named. Whether the seller names the compounding pharmacy that makes what it prescribes, so you can look that pharmacy up yourself.
- 10%Dosing guidance. Whether the product page prints a strength and a schedule, a schedule only, or neither.
- 10%Follow-up. Scheduled check-ins, unlimited messages, care included in the plan, or nothing stated.
- 10%Stays within legal scope. Whether the seller also lists peptides that have no lawful pharmacy route, next to the ones it may prescribe.
- 5%State coverage. How many states the seller serves. One that does not operate where you live is not an option.
- 5%Price against the market. A minor input: the seller's published monthly price against the middle of the market for the same peptide.
- 5%Price as the dose rises. For peptides whose dose steps up only: whether the price holds or is re-set at each step.
Whether a seller pays us is not an input to its score. A test flips a seller’s status and checks that its score does not move.
Some of the sellers ranked here pay us a commission. The seller the scoring function places first, Klarity Health, is not one of them. See disclosures for what a partner can and cannot get.
7.What this method does not do
- It does not rate whether a peptide works.
- It does not judge a seller’s prescribers.
- It does not give medical advice. See the medical disclaimer.